Allurion 2025 Q2 Earnings Narrowing Losses Amid Revenue Drop

Allurion Technologies reported its fiscal 2025 Q2 earnings on August 28, 2025, showing a narrowing loss per share despite a sharp decline in revenue. The company provided revenue guidance in line with expectations and anticipates continued cost efficiency as it progresses toward key regulatory milestones.

Revenue
Allurion’s total revenue for the second quarter of 2025 fell significantly to $3.38 million, a 71.3% decrease from $11.77 million in the same period of 2024. The drop reflects ongoing challenges in scaling its core offerings, with no segment-specific revenue details provided.

Earnings/Net Income
The company reduced its loss per share to $1.28 from $4.34 in 2024 Q2, marking a 70.5% improvement. However, the net loss expanded to $9.34 million in Q2 2025, a 12.2% increase from $8.32 million in the prior-year period. This suggests that while per-share losses are declining, overall financial performance remains challenging.

Price Action
ALUR’s stock edged up 0.45% on the latest trading day, gained 11.56% for the week, but dropped 20.43% month-to-date, reflecting mixed investor sentiment.

Post-Earnings Price Action Review
A strategy of buying ALUR on an earnings beat and holding for 30 days yielded a -51.04% return, underperforming the 22.93% benchmark. With a Sharpe ratio of -0.30 and a maximum drawdown of 0.00%, the approach failed to generate meaningful returns or manage risk effectively.

CEO Commentary
Dr. Shantanu Gaur, CEO, highlighted operational efficiency gains and a narrowed operating loss, citing reduced expenses and a stronger gross margin. He emphasized the strategic shift toward combination therapy with low-dose GLP-1 medications, which has gained traction among providers and patients. Gaur also noted the successful pre-PMA meeting with the FDA and progress on the final PMA submission, expressing confidence in the combination therapy’s potential to address unmet GLP-1 market needs.

Guidance
Allurion maintains 2025 revenue guidance of approximately $30 million and expects a 50% reduction in operating expenses compared to 2024. The company anticipates completing its PMA submission by year-end and initiating a trial on the Allurion Program’s combination with low-dose GLP-1 medications.

Additional News
On July 7, 2025, Allurion’s news section indicated ongoing updates and a dynamic content filter by year. While no immediate M&A activity or executive changes were reported, the company remains focused on its strategic and regulatory advancements. Investors are encouraged to monitor the firm’s progress on the PMA and combination therapy trial as key catalysts for future growth.